CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $266.76M, lower than 95% of all stocks globally
- PositionOperating margin is -271.9%, lower than 95% of its Medical Devices peers (median 8.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
266.76MUSDvs all stocks (USD)
Revenue (TTM)
40.71MUSDvs all stocks (USD)
Profit Margin
-214.16%vs Medical Devices peers
Beta
0.9920xvs all stocks
52-Week Change
-55.80%vs all stocks
Market Capitalization
266.76MUSDvs all stocks (USD)
Enterprise Value
192.39MUSDvs all stocks (USD)
Forward P/E
-2.33xvs Medical Devices peers
Price to Sales (TTM)
6.55xvs Medical Devices peers
Price to Book (MRQ)
6.22xvs Medical Devices peers
Enterprise to Revenue
4.73xvs Medical Devices peers
Enterprise to EBITDA
-2.26xvs Medical Devices peers
Gross Margin
59.26%vs Medical Devices peers
Profit Margin
-214.16%vs Medical Devices peers
Operating Margin
-271.93%vs Medical Devices peers
Return on Assets (TTM)
-57.02%vs Medical Devices peers
Return on Equity (TTM)
-250.78%vs Medical Devices peers
Revenue (TTM)
40.71MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.9210USDUpdated Jul 19, 2026Quarterly Revenue Growth
87.20%vs Medical Devices peers
Gross Profit (TTM)
21.20MUSDvs all stocks (USD)
EBITDA (TTM)
-85.02MUSDvs all stocks (USD)
Net Income (TTM)
-87.19MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-75.07MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-46.15MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
35.26MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
19.49MUSDFY2025 · Dec 31, 2025Gross Profit
15.76MUSDFY2025 · Dec 31, 2025Operating Income
-68.34MUSDvs all stocks (USD)
Pre-tax Income
-69.11MUSDFY2025 · Dec 31, 2025Net Income
-69.11MUSDFY2025 · Dec 31, 2025EBIT
-64.16MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-62.65MUSDFY2025 · Dec 31, 2025Research & Development
31.59MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
52.51MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
4.95MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-69.11MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-64.58MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
40.55MUSDFY2025 · Dec 31, 2025Interest Paid
4.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-69.11MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.51MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.15MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.32MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.76MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.22MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.91MUSDFY2025 · Dec 31, 2025Purchase of Investments
-100.69MUSDFY2025 · Dec 31, 2025Sale of Investments
48.39MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-52.31MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-20.40MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.15MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
78.05MUSDFY2025 · Dec 31, 2025Shares Outstanding
41.80MSharesUpdated Jul 19, 2026Float Shares
38.47MSharesUpdated Jul 19, 2026Shares Short
5.79MSharesUpdated Jul 19, 2026Short Ratio
6.68daysvs all stocks
Short % of Shares Outstanding
11.39%vs all stocks
% Held by Insiders
12.44%vs all stocks
% Held by Institutions
21.10%vs all stocks
Total Cash (MRQ)
64.32MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.54USDUpdated Jul 19, 2026Total Debt (MRQ)
43.14MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.26xvs Medical Devices peers
Current Ratio (MRQ)
3.50xvs Medical Devices peers
Book Value per Share (MRQ)
0.8220USDUpdated Jul 19, 2026Total Assets
126.27MUSDvs all stocks (USD)
Total Current Assets
117.53MUSDFY2025 · Dec 31, 2025Total Liabilities
65.22MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.74MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
40.88MUSDFY2025 · Dec 31, 2025Total Current Liabilities
24.35MUSDFY2025 · Dec 31, 2025Cash
6.61MUSDFY2025 · Dec 31, 2025Cash Equivalents
33.62MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
40.23MUSDFY2025 · Dec 31, 2025Other Short-term Investments
53.80MUSDFY2025 · Dec 31, 2025Accounts Receivable
12.12MUSDFY2025 · Dec 31, 2025Inventory
6.70MUSDFY2025 · Dec 31, 2025Accounts Payable
4.06MUSDFY2025 · Dec 31, 2025Short-term Debt
496.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
532.00KUSDFY2025 · Dec 31, 2025Long-term Debt
40.88MUSDFY2025 · Dec 31, 2025Common Stock (Book)
41.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.02BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
61.05MUSDvs all stocks (USD)
52-Week Low
4.79USDUpdated Jul 19, 202652-Week High
12.52USDUpdated Jul 19, 202652-Week Change
-55.80%vs all stocks
Beta
0.9920xvs all stocks
50-Day MA
6.05USDUpdated Jul 19, 2026200-Day MA
6.72USDUpdated Jul 19, 2026Avg 10-Day Volume
544.20KSharesUpdated Jul 19, 2026Avg 30-Day Volume
789.97KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.97USDUpdated Jul 19, 2026Other Income / Expense
-23.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -271.9%, lower than 95% of its Medical Devices peers (median 8.1%)Significant
Operating margin: -2.72Industry median: 0.08Industry P5: -0.73Peers compared: 102
Profit margin is -214.2%, lower than 95% of its Medical Devices peers (median 4.8%)Significant
Profit margin: -2.14Industry median: 0.05Industry P5: -1.45Peers compared: 102
Return on equity is -250.8%, lower than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: -2.51Industry median: 0.03Industry P5: -0.69Peers compared: 102
Return on assets is -57%, lower than 95% of its Medical Devices peers (median 1.9%)Significant
Return on assets: -0.57Industry median: 0.02Industry P5: -0.55Peers compared: 102
Debt-to-equity is 1.26×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 1.26Industry median: 0.11Industry P95: 1.20Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.59Profit Margin: -2.14
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.67
High structural barrier to entryNotable
Barrier to Entry: 9.97
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $266.76M, lower than 95% of all stocks globallySignificant
Market cap (USD): 266,757,151Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Opus Genetics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sab Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Foghorn Therapeutics Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Viant Technology Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
ServiceNow, Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated